Dec. 9 at 1:57 PM
Citizens y'day reiterated
$RAPP Market Outperform-
$80 and said, 'New Data and Analyses Reinforce our Belief in the Best-In-Class Profile of RAP-219.'
$PRAX $XENE $BHVN $JAZZ
H.C. Wainwright⬆️the PT to
$40 from
$34 and reit'd at Buy after recent '219 data and said, these additional analyses reinforce our belief that RAP-219 is perhaps the most potent ASM ever seen and has a lot of dosing flexibility in Phase 3 to further improve its risk/benefit profile.
At the AES conference, we also sensed widespread physicians' enthusiasm for new therapies and a much more favorable reimbursement environment for branded ASMs, suggesting a growing market in early-line FOS patients. For example, epileptologists and neurologists attending the AES told us they had prescribed cenobamate as a 2L therapy after Keppra (levetiracetam) with little pushback from payers. As a result, we increase our estimated market size of refractory FOS, taking our PT to
$40 from
$34.
